NewsZydus Lifesciences Board Meeting Scheduled for May 19, 2026 to Consider Q4FY26 Results and Final DividendZydus Lifesciences Board Meeting Scheduled for May 19, 2026 to Consider Q4FY26 Results and Final Dividend
Zydus Lifesciences Limited has announced a Board of Directors meeting on May 19, 2026, to approve audited financial results for the quarter and year ended March 31, 2026, and to recommend a final dividend for the financial year ended March 31, 2026. The intimation was filed on May 8, 2026, under Regulation 29(1) of the SEBI (LODR) Regulations, 2015. The trading window for Directors and Designated Persons will remain closed until May 21, 2026, reopening from May 22, 2026, in line with SEBI insider trading regulations.
*this image is generated using AI for illustrative purposes only.
Zydus Lifesciences Limited has notified the stock exchanges of an upcoming Board of Directors meeting, pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting is scheduled for Tuesday, May 19, 2026, and will take up, among other agenda items, key financial and dividend-related decisions for the recently concluded fiscal year.
Board Meeting Agenda
The Board meeting has been convened to consider two primary items of business, as communicated through the official regulatory filing dated May 8, 2026:
- Approval of audited financial results for the quarter and year ended March 31, 2026
- Recommendation of final dividend for the Financial Year ended March 31, 2026
The following table summarizes the key details of the scheduled Board meeting:
| Parameter: | Details |
|---|---|
| Meeting Date: | Tuesday, May 19, 2026 |
| Purpose: | Approval of audited Q4FY26 financial results |
| Additional Agenda: | Recommendation of final dividend for FY ended March 31, 2026 |
| Regulatory Reference: | Regulation 29(1) of SEBI (LODR) Regulations, 2015 |
| Filing Date: | May 8, 2026 |
Trading Window Closure
In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has also communicated the applicable trading window restrictions for its Directors and Designated Persons. The trading window will remain closed until Thursday, May 21, 2026, and will reopen for trading on and from Friday, May 22, 2026.
| Parameter: | Details |
|---|---|
| Trading Window Closure: | Until Thursday, May 21, 2026 |
| Trading Window Reopens: | Friday, May 22, 2026 |
| Applicable To: | All Directors and Designated Persons of the Company |
Regulatory Filing Details
The intimation was submitted by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on behalf of Zydus Lifesciences Limited. The company is registered at 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India, with CIN: L24230GJ1995PLC025878.
The filing was made simultaneously to BSE Limited and the National Stock Exchange of India Limited, in compliance with applicable listing regulations.
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.03% | +5.40% | +7.62% | -0.43% | +6.08% | +55.84% |
How might Zydus Lifesciences' FY26 revenue and profit margins compare to FY25, given the competitive pressures in the generic pharmaceuticals market?
Will the final dividend for FY26 reflect an increase over the previous year, signaling improved cash flow generation and shareholder return strategy?
How could Zydus Lifesciences' Q4FY26 financial results influence analyst sentiment and institutional investor positioning in the stock post-May 22?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
